Monashee Investment Management LLC Takes Position in Carlsmed, Inc. $CARL

Monashee Investment Management LLC acquired a new position in Carlsmed, Inc. (NASDAQ:CARL) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 40,000 shares of the company’s stock, valued at approximately $536,000. Monashee Investment Management LLC owned 0.15% of Carlsmed at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. JPMorgan Chase & Co. purchased a new stake in shares of Carlsmed during the third quarter worth $37,000. Rhumbline Advisers bought a new stake in shares of Carlsmed during the 3rd quarter valued at $79,000. Board of Trustees of The Leland Stanford Junior University bought a new stake in shares of Carlsmed during the 3rd quarter valued at $335,000. Kornitzer Capital Management Inc. KS purchased a new stake in Carlsmed during the 3rd quarter worth about $736,000. Finally, TD Waterhouse Canada Inc. bought a new position in Carlsmed in the 3rd quarter worth about $2,026,000.

Carlsmed Price Performance

Shares of CARL opened at $14.57 on Friday. Carlsmed, Inc. has a 1-year low of $10.65 and a 1-year high of $17.19. The stock has a market capitalization of $389.46 million and a P/E ratio of -3.98. The company has a debt-to-equity ratio of 0.14, a current ratio of 12.03 and a quick ratio of 11.91. The company has a 50 day moving average of $12.68.

Carlsmed (NASDAQ:CARL) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. The business had revenue of $15.16 million during the quarter, compared to analysts’ expectations of $15.20 million. Carlsmed had a negative net margin of 58.67% and a negative return on equity of 251.27%.

Wall Street Analysts Forecast Growth

CARL has been the topic of several analyst reports. Truist Financial reiterated a “buy” rating and set a $20.00 price target (up from $18.00) on shares of Carlsmed in a research report on Friday, November 7th. BTIG Research reaffirmed a “buy” rating and set a $24.00 price objective on shares of Carlsmed in a research note on Monday, December 15th. Wall Street Zen upgraded shares of Carlsmed from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. Zacks Research downgraded shares of Carlsmed from a “hold” rating to a “strong sell” rating in a report on Wednesday. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $20.00 price target on shares of Carlsmed in a report on Friday, January 9th. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $21.33.

About Carlsmed

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).